tiprankstipranks
Aclaris Therapeutics (GB:0H8T)
LSE:0H8T

Aclaris Therapeutics (0H8T) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0H8T Analyst Ratings

Hold
4Ratings
0 Buy
4 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Aclaris
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0H8T Stock 12 Months Forecast

Average Price Target

$1.50
▲(17.65% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $1.50 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 17.65% change from the last price of $1.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.208,1.2689230769230768,1.329846153846154,1.3907692307692308,1.4516923076923076,1.5126153846153847,1.5735384615384616,1.6344615384615384,1.6953846153846155,1.7563076923076923,1.8172307692307692,1.8781538461538463,1.9390769230769231,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.208,1.2304615384615385,1.2529230769230768,1.2753846153846153,1.2978461538461539,1.3203076923076922,1.3427692307692307,1.3652307692307692,1.3876923076923076,1.410153846153846,1.4326153846153846,1.455076923076923,1.4775384615384615,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.208,1.192,1.176,1.16,1.144,1.128,1.112,1.096,1.08,1.064,1.048,1.032,1.016,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.87,"date":1679616000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.054,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.889,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.598,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.085,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.87,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.529,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.904,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.208,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2.00Average Price Target$1.50Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus
$1.00
Hold
-21.57%
Downside
Reiterated
12/19/23
Stifel Nicolaus Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)
Piper Sandler
$2.00
Hold
56.86%
Upside
Downgraded
11/13/23
Hold Rating on Aclaris Therapeutics: Unfavorable ATI-450 Trial Results and Uncertainty on Upcoming ATI-1777 Trial
William Blair
Hold
Downgraded
11/13/23
Aclaris Therapeutics downgraded to Market Perform at William BlairAclaris Therapeutics downgraded to Market Perform at William Blair
Cantor Fitzgerald
Hold
Downgraded
11/13/23
Aclaris Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldAclaris Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Goldman Sachs
Buy
Reiterated
08/07/23
Wall Street Analysts Are Bullish on Top Healthcare Picks
Evercore ISI Analyst forecast on GB:0H8T
Unknown Analyst
Not Ranked
Evercore ISI
$22.00
Buy
1625.49%
Upside
Initiated
10/03/23
Aclaris Therapeutics initiated with an Outperform at Evercore ISIAclaris Therapeutics initiated with an Outperform at Evercore ISI

Best Analysts Covering Aclaris Therapeutics

Which Analyst Should I Follow If I Want to Buy GB:0H8T and Sell After:
1 Month
Corinne JohnsonGoldman Sachs
Success Rate
2/4 ratings generated profit
50%
Average Return
+3.92%
reiterated a buy rating 8 months ago
Copying Corinne Johnson's trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.92% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Corinne JohnsonGoldman Sachs
Success Rate
2/4 ratings generated profit
50%
Average Return
-8.50%
reiterated a buy rating 8 months ago
Copying Corinne Johnson's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -8.50% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Corinne JohnsonGoldman Sachs
Success Rate
0/4 ratings generated profit
0%
Average Return
-87.22%
reiterated a buy rating 8 months ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -87.22% per trade.
2 Years
Corinne JohnsonGoldman Sachs
Success Rate
0/4 ratings generated profit
0%
Average Return
-87.35%
reiterated a buy rating 8 months ago
Copying Corinne Johnson's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -87.35% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0H8T Analyst Recommendation Trends

Rating
Nov 23
Dec 23
Jan 24
Feb 24
Mar 24
Strong Buy
13
10
7
3
1
Buy
1
0
0
0
0
Hold
5
7
12
8
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
17
19
11
8
In the current month, 0H8T has received 1 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 0H8T average Analyst price target in the past 3 months is $1.50.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0H8T Financial Forecast

0H8T Earnings Forecast

Next quarter’s earnings estimate for 0H8T is -$0.28 with a range of -$0.37 to -$0.08. The previous quarter’s EPS was -$0.02. 0H8T beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.62% of the time in the same period. In the last calendar year 0H8T has Outperformed its overall industry.
Next quarter’s earnings estimate for 0H8T is -$0.28 with a range of -$0.37 to -$0.08. The previous quarter’s EPS was -$0.02. 0H8T beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.62% of the time in the same period. In the last calendar year 0H8T has Outperformed its overall industry.

0H8T Sales Forecast

Next quarter’s sales forecast for 0H8T is $2.00M with a range of $566.00K to $5.30M. The previous quarter’s sales results were $17.57M. 0H8T beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0H8T has Outperformed its overall industry.
Next quarter’s sales forecast for 0H8T is $2.00M with a range of $566.00K to $5.30M. The previous quarter’s sales results were $17.57M. 0H8T beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0H8T has Outperformed its overall industry.

0H8T Stock Forecast FAQ

What is GB:0H8T’s average 12-month price target, according to analysts?
Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is $1.50.
    What is GB:0H8T’s upside potential, based on the analysts’ average price target?
    Aclaris Therapeutics has 17.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Aclaris Therapeutics a Buy, Sell or Hold?
          Aclaris Therapeutics has a conensus rating of Hold, which is based on 0 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Aclaris Therapeutics’s share price target?
            The average share price target for Aclaris Therapeutics is $1.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2.00 ,and the lowest forecast is $1.00. The average share price target represents 17.65% Increase from the current price of $1.275.
              What do analysts say about Aclaris Therapeutics?
              Aclaris Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Aclaris Therapeutics?
                To buy shares of GB:0H8T, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis